Clinical factors related to long-term administration of sorafenib in patients with hepatocellular carcinoma

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 423-429

  Nojiri, Shunsuke ^a   Kusakabe, Atsunori ^a   Fujiwara, Kei ^a   Shinkai, Noboru ^a   Matsuura, Kentaro ^a   Iio, Etsuko ^a   Miyaki, Tomokatsu ^a   Nomura, Tomoyuki ^b   Sobue, Satoshi ^c   Sano, Hitoshi ^d   Hasegawa, Izumi ^e   Ohno, Tomoyoshi ^e   Takahashi, Yoshitsugu ^f   Orito, Etsuro ^g   Joh, Takashi ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Inabe General Hospital   (Japan)

^c Kasugai Municipal Hospital   (Japan)

^d Tajimi Prefectural Hospital   (Japan)

^e CHUKYO HOSPITAL   (Japan)

^f Chita Kousei Hospital   (Japan)

^g NAGOYA DAINI RED CROSS HOSPITAL   (Japan)

Author keywords

Discontinuation; Efficacy; Hepatocellular continuation; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; DECARBOXYPROTHROMBIN; SORAFENIB;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; ASCITES; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHRONIC DRUG ADMINISTRATION; CLINICAL EVALUATION; DIARRHEA; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG RESPONSE; DRUG WITHDRAWAL; FATIGUE; FEMALE; HAND FOOT SYNDROME; HEPATIC ENCEPHALOPATHY; HUMAN; JAUNDICE; KIDNEY FAILURE; LIVER CELL CARCINOMA; LIVER DYSFUNCTION; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PANCREATITIS; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; SIDE EFFECT; TREATMENT DURATION;

EID: 84871636162     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S38684     Document Type: Article

References (42)

1. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology. 2002;35:519-524.
2. Park KW, Park JW, Choi JI., et al. Survival analysis of 904 patients with hepatocellular carcinoma in a hepatitis B virus-endemic area. J Gastroenterol Hepatol. 2008;23:467-473.
3. Mazzaferro V, Regalia E, Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
4. Llovet JM, Real MI, Montana X., et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet. 2002;359:1734-1739.
5. Lo CM, Ngan H, Tso WK., et al. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology. 2002;35:1164-1171.
6. Varela M, Real MI, Burrel M., et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics. J Hepatol. 2007;46:474-481.
7. Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020-1022.
8. Shiratori Y, Shiina S, Teratani T., et al. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med. 2003;138: 299-306.
9. Muto Y, Moriwaki H, Ninomiya M., et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N Engl J Med. 1996;334:1561-1567.
10. Muto Y, Sato S, Watanabe A., et al. Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis. Hepatol Res. 2006;35:204-214.
11. Semela D, Piguet AC, Kolev M., et al. Vascular remodeling and antitumoral effects of mTOR inhibition in a rat model of hepatocellular carcinoma. J Hepatol. 2007;46:840-848.
12. Dempke WC, Zippel R. Brivanib. A novel dual VEGF-R2/bFGF-R inhibitor. Anticancer Res. 2010;30:4477-4483.
13. Huynh H. Molecularly targeted therapy in hepatocellular carcinoma. Biochem Pharmacol. 2010;80:550-560.
14. Kudo M. Hepatocellular carcinoma 2009 and beyond: from the surveillance to molecular targeted therapy. Oncology. 2008;75 Suppl 1: 1-12.
15. Villanueva A, Llovet JM. Targeted therapies for hepatocellular carcinoma. Gastroenterology. 2011;140:1410-1426.
16. Wilhelm SM, Carter C, Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004;64:7099-7109.
17. Chang YS, Adnane J, Trail PA., et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol. 2007;59:561-574.
18. Coriat R, Nicco C, Chereau C., et al. Sorafenib-induced hepatocellular carcinoma cell death depends on reactive oxygen species production in vitro and in vivo. Mol Cancer Ther. 2012;11:2284-2293.
19. Wilhelm SM, Adnane L, Newell P., et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther. 2008;7:3129-3140.
20. Llovet JM, Ricci S, Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med. 2008;359:378-390.
21. Cheng AL, Kang YK, Chen Z., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 2009;10:25-34.
22. Otsuka T, Eguchi Y, Kawazoe S., et al. Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib. Hepatol Res. 2012;42:879-886.
23. Lencioni R, Llovet JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis. 2010;30:52-60.
24. Shim JH, Park JW, Choi JI., et al. Practical efficacy of sorafenib monotherapy for advanced hepatocellular carcinoma patients in a Hepatitis B virus-endemic area. J Cancer Res Clin Oncol. 2009;135:617-625.
25. Han KH, Kudo M, Ye SL., et al. Asian consensus workshop report: expert consensus guideline for the management of intermediate and advanced hepatocellular carcinoma in Asia. Oncology. 2011;81 Suppl 1: 158-164.
26. Llovet JM, Di Bisceglie AM, Bruix J., et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst. 2008;100:698-711.
27. Kudo M. Adjuvant therapy after curative treatment for hepatocellular carcinoma. Oncology. 2011;81 Suppl 1:50-55.
28. Weinmann A, Niederle IM, Koch S., et al. Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation. Dig Liver Dis. 2012;44:432-437.
29. Gomez-Martin C, Bustamante J, Castroagudin JF., et al. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2012;18:45-52.
30. Sansonno D, Lauletta G, Russi S., et al. Transarterial chemoembolization plus sorafenib: a sequential therapeutic scheme for HCV-related intermediate-stage hepatocellular carcinoma: a randomized clinical trial. Oncologist. 2012;17:359-366.
31. Park JW, Koh YH, Kim HB., et al. Phase II study of concurrent transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma. J Hepatol. 2012;56:1336-1342.
32. Lacouture ME, Reilly LM, Gerami P., et al. Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008;19:1955-1961.
33. Lacouture ME, Wu S, Robert C., et al. Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008;13: 1001-1011.
34. Rombola F, Caravetta A, Mollo F., et al. Sorafenib, risk of bleeding and spontaneous rupture of hepatocellular carcinoma. A clinical case. Acta Medica (Hradec Kralove). 2011;54:177-179.
35. Boudou-Rouquette P, Ropert S, Mir O., et al. Variability of sorafenib toxicity and exposure over time: a pharmacokinetic/pharmacodynamic analysis. Oncologist. 2012;17:1204-1212.
36. Vincenzi B, Santini D, Russo A., et al. Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib. Oncologist. 2010;15:85-92.
37. Bettinger D, Schultheiss M, Knuppel E., et al. Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma. Hepatology. 2012;56:789-790.
38. Zhao Y, Yang M, Qi X., et al. Drug-related adverse events may predict efficacy in sorafenib therapy for hepatocellular carcinoma. Hepatology. 2012;56:790-791.
39. Horger M, Lauer UM, Schraml C., et al. Early MRI response monitoring of patients with advanced hepatocellular carcinoma under treatment with the multikinase inhibitor sorafenib. BMC Cancer. 2009;9:208.
40. Lee JH, Park JY, Kim do Y., et al. Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib. Liver Int. 2011;31:1144-1149.
41. Okuwaki Y, Nakazawa T, Hidaka H., et al. Late-onset benefit in progressive advanced hepatocellular carcinoma with continued sorafenib therapy: a case report. J Med Case Rep. 2012;6:38.
42. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908-943.